Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL11338578 | 0.95 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL6510255 | 0.95 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11338580 | 0.95 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11307929 | 0.95 | LMNA (0.67) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11765690 | 0.95 | LMNA (0.67) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11152373 | 0.95 | LMNA (0.67) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL1761127 | 0.95 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL10771333 | 0.95 | LMNA (0.67) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL21273372 | 0.95 | FFAR3 (0.78) | FFAR3LCKFYNLMNATSHR | |
| Benzene SCHEMBL11545210 | 0.95 | LMNA (0.67) | FFAR3LCKFYNLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730786-B2 | High molecular weight polysaccharide that binds and inhibits virus | WORLD FORCE TECHNOLOGIES, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210008143-A1 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS | WORLD FORCE TECH LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-10842840-B2 | High molecular weight polysaccharide that binds and inhibits virus | WORLD FORCE TECHNOLOGIES, LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190321434-A1 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS | WORLD FORCE TECH LLC (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2019182483-A1 | PEPTIDE SUBSTRATES FOR PAPAIN FAMILY CYSTEINE PEPTIDASES | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" | 2019-09-26 | — | — | WO | disclosed |
| US-10232007-B2 | High molecular weight polysaccharide that binds and inhibits virus | WORLD FORCE TECHNOLOGIES, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180000882-A1 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS | WORLD FORCE TECH LLC (US) | 2018-01-04 | — | — | US | disclosed |
| US-9707263-B2 | High molecular weight polysaccharide that binds and inhibits virus | WORLD FORCE TECHNOLOGIES, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170158735-A1 | METHOD FOR PRODUCING A RECOMBINANT PEPTIDE AND RESULTANT PEPTIDE | "IVIX" LTD. (RU) | 2017-06-08 | — | — | US | disclosed |
| US-9409947-B2 | Method for producing a recombinant peptide and resultant peptide | “IVIX” LTD. (RU) | 2016-08-09 | — | — | US | disclosed |
| WO-2001003647-A2 | MICROBIAL PROCESS FOR PREPARING PRAVASTATIN | IVAX CORPORATION (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-1037904-A2 | BRANCHED BUILDING UNITS FOR SYNTHESIZING CYCLIC PEPTIDES | PEPTOR LTD (IL) | 2000-09-27 | — | — | EP | disclosed |
| EP-0947584-A1 | LOXOPROFEN-CONTAINING PREPARATION FOR EXTERNAL USE | LEAD CHEMICAL COMPANY LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999031121-A2 | BRANCHED BUILDING UNITS FOR SYNTHESIZING CYCLIC PEPTIDES | PEPTOR LTD. (IL) | 1999-06-24 | — | — | WO | disclosed |
| US-4652531-A | Fluorescent protein binding assays with unsymmetrical fluorescein derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4615986-A | USING A MACROMOLECULAR SUPPORT | SYNTEX (U.S.A.) INC. (US) | 1986-10-07 | — | — | US | disclosed |
| US-4508892-A | Compositions for competitive protein binding assays inhibiting non-specific interference | SYVA COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| EP-0015695-B1 | SUPPORT-LIGAND ANALOG-FLUORESCER CONJUGATE AND SERUM ASSAY METHOD INVOLVING SUCH CONJUGATE | SYVA COMPANY (US) | 1984-11-14 | — | — | EP | disclosed |
| US-4439356-A | XANTHENES, IMMUNOASSAY | SYVA COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0015695-A1 | Support-ligand analog-fluorescer conjugate and serum assay method involving such conjugate | SYVA COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10232007-B2 | High molecular weight polysaccharide that binds and inhibits virus | CD44, LIMS1, LGALS1 | FFAR3 4832/4885LCK 2681/4885FYN 1683/4885 |
| US-20180000882-A1 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS | CD44, LIMS1, LGALS1 | FFAR3 4832/4885LCK 2681/4885FYN 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.